This study is testing a new treatment (JNJ-79635322) for Multiple Myeloma, a type of blood cancer. Researchers want to figure out the best dose and schedule when this drug is used with other drugs like daratumumab, lenalidomide, or pomalidomide. The goal is to find the safest and most effective way to use these drugs together. To join, you need to have multiple myeloma and meet certain health conditions. You cannot join if you have serious health issues or have had certain treatments in the past.
- Study involves different treatment groups and may require several visits.
- Participants must have been treated for multiple myeloma before or be newly diagnosed.
- There may be some risks, so eligibility criteria are strict.